WO1999058675A3 - Human genes and gene expression products v - Google Patents

Human genes and gene expression products v Download PDF

Info

Publication number
WO1999058675A3
WO1999058675A3 PCT/US1999/010602 US9910602W WO9958675A3 WO 1999058675 A3 WO1999058675 A3 WO 1999058675A3 US 9910602 W US9910602 W US 9910602W WO 9958675 A3 WO9958675 A3 WO 9958675A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
gene expression
expression products
human genes
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/010602
Other languages
French (fr)
Other versions
WO1999058675A2 (en
Inventor
Lewis T Williams
Jaime Escobedo
Michael A Innis
Pablo Dominguez Garcia
Julie Sudduth-Klinger
Christoph Reinhard
Klaus Giese
Filippo Randazzo
Giulia C Kennedy
David Pot
Altaf Kassam
George Lamson
Radoje Drmanac
Radomir Crkvenjakov
Mark Dickson
Snezana Drmanac
Ivan Labat
Dena Leshkowitz
David Kita
Veronica Garcia
Lee William Jones
Birgit Stache-Crain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Hyseq Inc
Original Assignee
Hyseq Inc
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc, Chiron Corp filed Critical Hyseq Inc
Priority to AU41874/99A priority Critical patent/AU4187499A/en
Priority to EP99925624A priority patent/EP1105474A2/en
Priority to JP2000548466A priority patent/JP2002534055A/en
Publication of WO1999058675A2 publication Critical patent/WO1999058675A2/en
Publication of WO1999058675A3 publication Critical patent/WO1999058675A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.
PCT/US1999/010602 1998-05-14 1999-05-13 Human genes and gene expression products v Ceased WO1999058675A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU41874/99A AU4187499A (en) 1998-05-14 1999-05-13 Human genes and gene expression products v
EP99925624A EP1105474A2 (en) 1998-05-14 1999-05-13 Human genes and gene expression products v
JP2000548466A JP2002534055A (en) 1998-05-14 1999-05-13 Human gene and gene expression product V

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US8542698P 1998-05-14 1998-05-14
US8569698P 1998-05-15 1998-05-15
US8553798P 1998-05-15 1998-05-15
US10523498P 1998-10-21 1998-10-21
US60/105,234 1998-10-21
US10587798P 1998-10-27 1998-10-27
US60/085,696 1998-10-27
US60/085,537 1998-10-27
US60/085,426 1998-10-27
US60/105,877 1998-10-27

Publications (2)

Publication Number Publication Date
WO1999058675A2 WO1999058675A2 (en) 1999-11-18
WO1999058675A3 true WO1999058675A3 (en) 2000-02-17

Family

ID=27536405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010602 Ceased WO1999058675A2 (en) 1998-05-14 1999-05-13 Human genes and gene expression products v

Country Status (5)

Country Link
US (1) US7122373B1 (en)
EP (1) EP1105474A2 (en)
JP (1) JP2002534055A (en)
AU (1) AU4187499A (en)
WO (1) WO1999058675A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE359291T1 (en) 1998-02-05 2007-05-15 Univ Maryland BREAST CANCER RESISTANCE PROTEIN (BCRP) AND DNA CODING FOR IT
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
PT1626058E (en) * 1999-03-08 2008-02-15 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1196575A2 (en) * 1999-07-19 2002-04-17 Incyte Genomics, Inc. Gtp-binding protein associated factors
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US20040033509A1 (en) 2000-07-18 2004-02-19 Millennium Pharmaceuticals, Inc. Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor
US7301016B2 (en) 2000-03-07 2007-11-27 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
PT1290023E (en) * 2000-03-31 2011-01-05 Aventis Pharma Inc Nuclear factor kb inducing factor
US6500657B1 (en) * 2000-03-31 2002-12-31 Millennium Pharmaceuticals, Inc. 33167, a novel human hydrolase and uses therefor
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
DE60138952D1 (en) * 2000-03-31 2011-04-28 Millenium Pharmaceuticals Inc 16836, A MEMBER OF THE HUMAN PHOSPHOLIPASE C FAMILY AND ITS USES
US20060058516A1 (en) * 2000-04-10 2006-03-16 Burkhard Scharm Novel serine-threonine kinase
US7034135B2 (en) 2000-05-03 2006-04-25 Millennium Pharmaceuticals, Inc. Molecules of the NBS/LRR protein family and uses thereof
WO2001083753A2 (en) * 2000-05-03 2001-11-08 Millennium Pharmaceuticals, Inc. Molecules of the nbs/lrr protein family and uses thereof
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
WO2002000704A2 (en) * 2000-06-29 2002-01-03 Bayer Aktiengesellschaft Regulation of human phospholipase c-like enzyme
JP2004524003A (en) * 2000-06-29 2004-08-12 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of lung cancer
WO2002002771A2 (en) * 2000-07-05 2002-01-10 Eli Lilly And Company Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
AU2001286757A1 (en) * 2000-08-24 2002-03-04 Millenium Pharmaceuticals, Inc. 46863, a human methyltransferase and uses thereof
AU2001293780A1 (en) * 2000-08-30 2002-03-13 Bayer Aktiengesellschaft Regulation of human protein phosphatase iic-like enzyme
EP1317486A1 (en) * 2000-09-14 2003-06-11 Pharma Pacific Pty. Ltd. Interferon-alpha induced gene
AU2001293846A1 (en) * 2000-09-28 2002-04-08 Bayer Aktiengesellschaft Regulation of a human serine protease
EP1349934A2 (en) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
GB0029549D0 (en) * 2000-12-04 2001-01-17 Inpharmatica Ltd Novel protein
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
US6642041B2 (en) 2001-02-05 2003-11-04 Bristol-Meyers Squibb Company Polynucleotides encoding a novel metalloprotease, MP-1
EP1373485A2 (en) * 2001-03-27 2004-01-02 Novartis AG Ikk2 variant, dino gene, lectin-like receptor gene, and proteins encoded thereby
AU2002258728A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
US6528268B1 (en) 2001-08-03 2003-03-04 Sequenom-Gemini Limted Reagents and methods for detection of heart failure
WO2003018620A2 (en) * 2001-08-27 2003-03-06 Les Laboratoires Aeterna Inc. Serine protease inhibitor and processes for the preparation thereof
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
WO2003097872A2 (en) * 2002-05-21 2003-11-27 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
EP1365242A1 (en) * 2002-05-21 2003-11-26 MTM Laboratories AG Compounds for detection and treatment of colorectal lesions
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004035789A1 (en) * 2002-10-18 2004-04-29 Lg Life Sciences Ltd. Gene families associated with cancers
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CA2735578C (en) 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
EA201391017A1 (en) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. METHODS AND READY MEDICATION FORMS FOR THE TREATMENT OF ALZHEYMER
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BALDI ET AL: "Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer", CLINICAL CANCER RESEARCH, vol. 2, no. 2, July 1996 (1996-07-01), pages 1239 - 1245 45, XP002099965, ISSN: 1078-0432 *
CARMECI ET AL: "Identification of a gene (GPR30) with homolgy to the G-protein -coupled receptor superfamily associated with estrogen receptor expression in breast cancer", GENOMICS, vol. 45, no. 3, 1 November 1997 (1997-11-01), pages 607 - 617 17, XP002099963, ISSN: 0888-7543 *
J.H.MORISSEY: "Human tissue factor gene", EMBL DATABANK, ID HSTFPB, 20 February 1989 (1989-02-20), XP002114962 *
RADINSKY ET AL: "Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells", CLINICAL CANCER RESEARCH, vol. 1, no. 1, January 1995 (1995-01-01), pages 19 - 31 31, XP002099964, ISSN: 1078-0432 *
YEATMAN ET AL.: "Identification of a differentially-expressed mesage associated with colon cancer liver metastasis using an improved method of differential display", NUCLEIC ACIDS RESEARCH, vol. 23, no. 19, 1995, pages 4007/4008 8, XP002099962, ISSN: 0305-1048 *
YEATMAN ET AL: "Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse", CLINICAL & EXPERIMENTAL METASTASIS, vol. 14, no. 3, May 1996 (1996-05-01), pages 246 - 252 252, XP002099961, ISSN: 0262-0898 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response

Also Published As

Publication number Publication date
WO1999058675A2 (en) 1999-11-18
US7122373B1 (en) 2006-10-17
EP1105474A2 (en) 2001-06-13
AU4187499A (en) 1999-11-29
JP2002534055A (en) 2002-10-15

Similar Documents

Publication Publication Date Title
WO1999038972A3 (en) Human genes and gene expression products ii
WO1999058675A3 (en) Human genes and gene expression products v
WO1999033982A3 (en) Human genes and gene expression products i
WO2001066753A3 (en) Human genes and gene expression products
WO2002014500A3 (en) Human genes and gene expression products
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO1999064594A3 (en) Genes and gene expression products that are differentially regulated in prostate cancer
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2000012702A3 (en) Human genes differentially expressed in colorectal cancer
WO2001064877A3 (en) Human schizophrenia gene
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2000018916A3 (en) Human genes and gene expression products
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2003050236A3 (en) Human genes and gene expression products isolated from human prostate
WO2001072781A3 (en) Human genes and expression products
WO2000061774A3 (en) Bone morphogenic proteins
WO2001064876A3 (en) Human schizophrenia gene
WO1999046375A3 (en) Human nucleic acid sequences from prostate tissue
WO2001014415A3 (en) Egfh2 genes and gene products
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 548466

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999925624

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1999925624

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999925624

Country of ref document: EP